Breast Cancer and HER2-Low: A Distinct Biology or an Artifact of Testing?

New Perspectives on the Full Spectrum of HER2 Expression in Breast CancerПодробнее

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysisПодробнее

The evolution of HER2-low-positive breast cancer as a clinical subtypeПодробнее

A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast CancerПодробнее

Is HER2-low a distinct subtype of breast cancer?Подробнее

#BREASTPATH Destiny of HER2/neu in the era of HER2-low in 2024Подробнее

HER2-low is not a distinct subtype in inflammatory breast cancerПодробнее

The Science of HER2-low Breast Cancer and Implications for the Pathology TeamПодробнее

Clinical and molecular characteristics of HER2-low/zero early stage triple-negative breast cancerПодробнее

HER2 Low Breast Cancer A New Therapeutic Subtype | 2023 KU Breast Cancer Year in Review ConferenceПодробнее

Questions remaining in the field of HER2-low breast cancerПодробнее

HER2-low breast cancer: the ESMO Expert Consensus StatementsПодробнее

HER2-low as a separate entity for defining HER2 BC and its prognostic and biological significanceПодробнее

Findings indicate HER2-low and HER2-negative breast cancer are biology indistinctПодробнее

Biological behaviour of HER2-low BC is dependent on HR expressionПодробнее

The HER Pathway and CancerПодробнее

HER2 Testing in Gastroesophageal CancersПодробнее

HER2 in CancerПодробнее

The genomic characterization of primary and metastatic HER2-low breast cancersПодробнее